Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents

Shilong Li, Tomi Jun, Zichen Wang, Yu-Han Kao, Emilio Schadt, Maximilian F. Konig, Chetan Bettegowda, Joshua T. Vogelstein, Nickolas Papadopoulos, Ramon E. Parsons, Rong Chen, Eric E. Schadt, View ORCID ProfileLi Li, William K. Oh
doi: https://doi.org/10.1101/2021.04.08.21255148
Shilong Li
1Sema4, Stamford, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomi Jun
2Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zichen Wang
1Sema4, Stamford, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Han Kao
1Sema4, Stamford, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilio Schadt
1Sema4, Stamford, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian F. Konig
3Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
4Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chetan Bettegowda
3Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
5Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua T. Vogelstein
6Department of Biomedical Engineering, Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA
7Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health at The Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nickolas Papadopoulos
3Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
8Department of Oncology and Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramon E. Parsons
2Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
10Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Chen
1Sema4, Stamford, CT, USA
9Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric E. Schadt
1Sema4, Stamford, CT, USA
9Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Li
1Sema4, Stamford, CT, USA
9Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Li Li
  • For correspondence: william.oh@sema4.com li.li@sema4.com
William K. Oh
1Sema4, Stamford, CT, USA
2Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
10Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: william.oh@sema4.com li.li@sema4.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Alpha-1-adrenergic receptor antagonists (α1-blockers) can abrogate pro-inflammatory cytokines and may improve outcomes among patients with respiratory infections. Repurposing readily available drugs such as α1-blockers could augment the medical response to the COVID-19 pandemic.

Objective To evaluate the association between α1-blocker exposure and COVID-19 mortality

Design Real-world evidence study

Setting Patient level data with 32,355 records tested for SARS-CoV-2 at the Mount Sinai Health System including 8,442 laboratory-confirmed cases extracted from five member hospitals in the New York City metropolitan area.

Participants 2,627 men aged 45 or older admitted with COVID-19 between February 24 and May 31, 2020

Exposures α1-blocker use as an outpatient or while admitted for COVID-19

Main Outcomes and Measures In-hospital mortality

Results Men exposed to α1-blockers (N=436) were older (median age 73 vs. 64 years, P<0.001) and more likely to have comorbidities than unexposed men (N=2,191). Overall, 758 (28.9%) patients died in hospital, 1,589 (60.5%) were discharged, and 280 (10.7%) were still hospitalized as of May 31, 2020. Outpatient exposure to α1-blockers was not associated with COVID-19 hospital outcomes, though there was a trend towards significance (OR 0.749, 95% CI 0.527-1.064; P=0.106). Conversely, inpatient use of α1-blockers was independently associated with improved in-hospital mortality in both multivariable logistic (OR 0.633, 95% CI 0.434-0.921; P=0.017) and Cox regression analyses (HR 0.721, 95% CI 0.572-0.908; P=0.006) adjusting for patient demographics, comorbidities, and baseline vitals and labs. Age-stratified analyses suggested greater benefit from inpatient α1-blocker use among younger age groups: Age 45-65 OR 0.384, 95% CI 0.164-0.896 (P=0.027); Age 55-75 OR 0.511, 95% CI 0.297-0.880 (P=0.015); Age 65-89 OR 0.810, 95% CI 0.509-1.289 (P=0.374).

Conclusions and Relevance Inpatient α1-blocker use was independently associated with improved COVID-19 mortality among hospitalized men. Clinical trials to assess the therapeutic value of α1-blockers in COVID-19 are warranted.

Competing Interest Statement

Sema4 is a for-profit company currently majority owned by the Icahn School of Medicine at Mount Sinai (ISMMS). RC, EES, LL and WKO receive compensation from Sema4 that includes equity in the company. In addition to their roles with Sema4, RC, EES, LL and WKO remain affiliated with ISSMS as part-time employees and faculty members. WKO also has consulted for AAA, Astellas, AstraZeneca, Bayer, Conjupro, Foundry, Janssen, Merck, Sanofi and TeneoBio. The JHU filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which NP, BV, KWK, and SZ are listed as inventors. JHU will not assert patent rights from this filing for treatment related to COVID-19. NP is a founder of, consultant to and holds equity in Thrive an Exact company. NP is a founder of and holds equity in Personal Genome Diagnostics. NP is an advisor to and holds equity in Cage Pharma, ManaTbio and NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Labs. CB, MFK, BV, KWK, and NP are also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies.

Funding Statement

JV is supported by grants from Microsoft Research and FastGrants

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Mount Sinai institutional review board (IRB): IRB-17-01245

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The Mount Sinai Health System database is not publicly available. We utilized Python and R, and their open-source libraries to conduct our analysis tailored to MSH data. Therefore, we are unable to publicly release the code since it is useless without the dataset available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents
Shilong Li, Tomi Jun, Zichen Wang, Yu-Han Kao, Emilio Schadt, Maximilian F. Konig, Chetan Bettegowda, Joshua T. Vogelstein, Nickolas Papadopoulos, Ramon E. Parsons, Rong Chen, Eric E. Schadt, Li Li, William K. Oh
medRxiv 2021.04.08.21255148; doi: https://doi.org/10.1101/2021.04.08.21255148
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents
Shilong Li, Tomi Jun, Zichen Wang, Yu-Han Kao, Emilio Schadt, Maximilian F. Konig, Chetan Bettegowda, Joshua T. Vogelstein, Nickolas Papadopoulos, Ramon E. Parsons, Rong Chen, Eric E. Schadt, Li Li, William K. Oh
medRxiv 2021.04.08.21255148; doi: https://doi.org/10.1101/2021.04.08.21255148

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8589)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1772)
  • Geriatric Medicine (169)
  • Health Economics (375)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (197)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10344)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (933)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (255)
  • Pediatrics (539)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1785)
  • Public and Global Health (3871)
  • Radiology and Imaging (627)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)